Harry welcomes back Andrew A. Radin, CEO of the drug discovery startup twoXAR, where scientists model pathogenesis computationally to identify potential drug molecules and, ideally shaving years off the drug development process.
The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.
